​

Ginkgo Bioworks Stock (NYSE:DNA)

ForecastRevenueOwnershipFinancialsChartTranscripts
Ginkgo Bioworks by TradingView

Previous Close

$8.25

52W Range

$5.00 - $45.20

50D Avg

$8.78

200D Avg

$9.42

Market Cap

$469.49M

Avg Vol (3M)

$1.73M

Beta

1.35

Div Yield

-

DNA Company Profile

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

834

IPO Date

Apr 19, 2021

Website

DNA Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 24Dec 23Dec 22
Service$53.07M$78.97M$298.58M
Product-$28.95M$35.45M
Foundry Revenue--$143.67M

Fiscal year ends in Dec 24 | Currency in USD

DNA Financial Summary

Dec 24Dec 23Dec 22
Revenue$227.04M$251.46M$477.71M
Operating Income$-559.76M$-864.41M$-2.21B
Net Income$-547.03M$-892.87M$-2.10B
EBITDA$-559.76M$-821.29M$-2.06B
Basic EPS$-10.54$-18.37$-50.15
Diluted EPS$-10.54$-18.37$-50.12

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q4 24Feb 25, 25 | 5:30 PM
Q3 24Nov 12, 24 | 5:30 PM
Q2 24Aug 08, 24 | 5:30 PM

Peer Comparison

TickerCompany
HEPAHepion Pharmaceuticals, Inc.
OCEAOcean Biomedical, Inc.
ELEVElevation Oncology, Inc.
ENVBEnveric Biosciences, Inc.